Technology

Scarless wound healing - a Global unmet need

Inflammation and immune system activation are normal and necessary in early wound healing. Chronic inflammation and over-activation of the immune system lead to abnormal wound healing and scarring, including hypertrophic scarring which is permanent.

No treatment has proved effective in stopping the process and reducing scarring.
A novel gene therapy is being developed to address the problem.

Pulmonary Fibrosis

Viral infections
Other pneumonia
In US on average 150,000 –200,000 cases /year

Traumatic Brain Injury (TBI)

Neuroinflammation may lead to acute or chronic handicap

o Cognitive dysfunction
o Balance problems

o Depression

2.8 million patients annually in USA (sourcing CDC 2024)

After Burn Injury / After Surgery

Hypertrophic scarring in up to 80% of severe burn injuries
Smoke injury to lungs in 20% of cases
Cost of burn care >$18 B/year in US
Post surgical scar may affect 5 million patients in North America

SCARLEXA and FIBREXA are proprietary gene vectors being developed for human use.

Applied in the wound (SCARLEXA) or inhaled (FIBREXA) delivers the genetic code for expression and production of anti-scarring peptides at the site of injury in skin and lungs, respectively.